ACET Adicet Bio Inc

Price (delayed)

$2.35

Market cap

$101.44M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.35

Enterprise value

-$60.02M

Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of 'off-the-shelf' gamma delta ...

Highlights
Adicet Bio's debt has decreased by 3.7% QoQ
The company's net income has shrunk by 157% YoY and by 24% QoQ
ACET's EPS has dropped by 134% year-on-year and by 23% since the previous quarter

Key stats

What are the main financial stats of ACET
Market
Shares outstanding
43.16M
Market cap
$101.44M
Enterprise value
-$60.02M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.52
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$142.99M
EBITDA
-$134.72M
Free cash flow
-$99.89M
Per share
EPS
-$3.35
Free cash flow per share
-$2.32
Book value per share
$4.52
Revenue per share
$0
TBVPS
$5.43
Balance sheet
Total assets
$233.26M
Total liabilities
$38.58M
Debt
$21.8M
Equity
$194.68M
Working capital
$166.12M
Liquidity
Debt to equity
0.11
Current ratio
9.4
Quick ratio
9.27
Net debt/EBITDA
1.2
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-49.9%
Return on equity
-57.7%
Return on invested capital
-256.8%
Return on capital employed
-67%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACET stock price

How has the Adicet Bio stock price performed over time
Intraday
0.86%
1 week
-3.69%
1 month
-21.67%
1 year
-70.18%
YTD
24.34%
QTD
24.34%

Financial performance

How have Adicet Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$152.04M
Net income
-$143.04M
Gross margin
N/A
Net margin
N/A
ACET's operating income has plunged by 169% YoY and by 24% from the previous quarter
The company's net income has shrunk by 157% YoY and by 24% QoQ
Adicet Bio's revenue has shrunk by 100% YoY
The gross profit has dropped by 100% year-on-year

Growth

What is Adicet Bio's growth rate over time

Valuation

What is Adicet Bio stock price valuation
P/E
N/A
P/B
0.52
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ACET's EPS has dropped by 134% year-on-year and by 23% since the previous quarter
ACET's price to book (P/B) is 65% lower than its 5-year quarterly average of 1.5 and 26% lower than its last 4 quarters average of 0.7
Adicet Bio's equity has decreased by 39% YoY and by 19% QoQ
Adicet Bio's revenue has shrunk by 100% YoY

Efficiency

How efficient is Adicet Bio business performance
Adicet Bio's ROIC has plunged by 145% YoY and by 27% from the previous quarter
ACET's ROE is down by 40% QoQ
Adicet Bio's return on assets has decreased by 37% QoQ

Dividends

What is ACET's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACET.

Financial health

How did Adicet Bio financials performed over time
The quick ratio has decreased by 44% YoY and by 15% from the previous quarter
ACET's current ratio is down by 43% year-on-year and by 15% since the previous quarter
Adicet Bio's debt is 89% lower than its equity
ACET's debt to equity has soared by 57% YoY and by 22% QoQ
Adicet Bio's equity has decreased by 39% YoY and by 19% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.